Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Enlabs

DB:8NL
Snowflake Description

Exceptional growth potential and undervalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8NL
DB
SEK960M
Market Cap
  1. Home
  2. DE
  3. Consumer Services
Company description

Enlabs AB (publ) creates entertainment in gaming, media, and solutions business areas. The last earnings update was 67 days ago. More info.


Add to Portfolio Compare Print
  • Enlabs has significant price volatility in the past 3 months.
8NL Share Price and Events
7 Day Returns
12.1%
DB:8NL
-6.8%
DE Hospitality
-0.6%
DE Market
1 Year Returns
-32.6%
DB:8NL
-48.1%
DE Hospitality
-20.9%
DE Market
8NL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Enlabs (8NL) 12.1% -33.7% -44.3% -32.6% - -
DE Hospitality -6.8% -31.3% -57.6% -48.1% -63.2% -70.6%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 8NL outperformed the Hospitality industry which returned -48.1% over the past year.
  • 8NL underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
8NL
Industry
5yr Volatility vs Market

Value

 Is Enlabs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Enlabs to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Enlabs.

DB:8NL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 4.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:8NL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Hospitality Unlevered Beta Simply Wall St/ S&P Global 0.78
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.782 (1 + (1- 22%) (1.4%))
0.86
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.86
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.86 * 5.44%)
4.29%

Discounted Cash Flow Calculation for DB:8NL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Enlabs is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:8NL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 4.29%)
2020 10.00 Analyst x2 9.59
2021 14.50 Analyst x2 13.33
2022 17.00 Analyst x2 14.99
2023 18.72 Est @ 10.12% 15.82
2024 20.02 Est @ 6.97% 16.23
2025 20.97 Est @ 4.76% 16.30
2026 21.65 Est @ 3.21% 16.14
2027 22.11 Est @ 2.13% 15.80
2028 22.41 Est @ 1.38% 15.36
2029 22.60 Est @ 0.85% 14.85
Present value of next 10 years cash flows €148.00
DB:8NL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €22.60 × (1 + -0.39%) ÷ (4.29% – -0.39%)
€481.42
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €481.42 ÷ (1 + 4.29%)10
€316.40
DB:8NL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €148.00 + €316.40
€464.40
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €464.40 / 62.83
€7.39
DB:8NL Discount to Share Price
Calculation Result
Exchange Rate EUR/SEK
(Reporting currency to currency of OM:NLAB)
10.981
Value per Share
(SEK)
= Value per Share in EUR x Exchange Rate (EUR/SEK)
= €7.39 x 10.981
SEK81.17
Non-primary Listing Adjustment Factor 1 share in DB:8NL represents 0.08272x of OM:NLAB
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.08272x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 81.17 x 0.08272
€6.71
Value per share (EUR) From above. €6.71
Current discount Discount to share price of €1.26
= -1 x (€1.26 - €6.71) / €6.71
81.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Enlabs is available for.
Intrinsic value
>50%
Share price is €1.26 vs Future cash flow value of €6.71
Current Discount Checks
For Enlabs to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Enlabs's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Enlabs's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Enlabs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Enlabs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8NL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €0.15
OM:NLAB Share Price ** OM (2020-04-03) in SEK SEK15.28
OM:NLAB Share Price converted to EUR reporting currency Exchange rate (SEK/ EUR) 0.091 €1.39
Germany Hospitality Industry PE Ratio Median Figure of 9 Publicly-Listed Hospitality Companies 21.1x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Enlabs.

DB:8NL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:NLAB Share Price ÷ EPS (both in EUR)

= 1.39 ÷ 0.15

9.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enlabs is good value based on earnings compared to the DE Hospitality industry average.
  • Enlabs is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Enlabs's expected growth come at a high price?
Raw Data
DB:8NL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 9.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
20.6%per year
Europe Hospitality Industry PEG Ratio Median Figure of 63 Publicly-Listed Hospitality Companies 0.96x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

DB:8NL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 9.25x ÷ 20.6%

0.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enlabs is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Enlabs's assets?
Raw Data
DB:8NL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €0.64
OM:NLAB Share Price * OM (2020-04-03) in SEK SEK15.28
OM:NLAB Share Price converted to EUR reporting currency Exchange rate (SEK/ EUR) 0.091 €1.39
Germany Hospitality Industry PB Ratio Median Figure of 12 Publicly-Listed Hospitality Companies 1.73x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:8NL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:NLAB Share Price ÷ Book Value per Share (both in EUR)

= 1.39 ÷ 0.64

2.19x

* Primary Listing of Enlabs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Enlabs is overvalued based on assets compared to the DE Hospitality industry average.
X
Value checks
We assess Enlabs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Hospitality industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Hospitality industry average (and greater than 0)? (1 check)
  5. Enlabs has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Enlabs expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Enlabs expected to grow at an attractive rate?
  • Enlabs's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Enlabs's earnings growth is expected to exceed the Germany market average.
  • Enlabs's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:8NL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8NL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 20.6%
DB:8NL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 20.2%
Germany Hospitality Industry Earnings Growth Rate Market Cap Weighted Average 28.9%
Germany Hospitality Industry Revenue Growth Rate Market Cap Weighted Average 4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8NL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8NL Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 96 1
2022-12-31 73 21 18 2
2021-12-31 61 17 15 2
2020-12-31 50 15 12 2
2020-04-06
DB:8NL Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 40 12 9
2019-09-30 37 11 9
2019-06-30 34 11 9
2019-03-31 32 9 8
2018-12-31 30 8 7
2018-09-30 29 7 6
2018-06-30 28 7 6
2018-03-31 26 7 5
2017-12-31 23 6 4
2017-09-30 15 5 2
2017-06-30 16 -3 5
2017-03-31 16 2 5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Enlabs's earnings are expected to grow significantly at over 20% yearly.
  • Enlabs's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8NL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Enlabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8NL Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 0.31 0.33 0.29 2.00
2021-12-31 0.27 0.30 0.24 2.00
2020-12-31 0.20 0.21 0.20 2.00
2020-04-06
DB:8NL Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 0.15
2019-09-30 0.14
2019-06-30 0.13
2019-03-31 0.12
2018-12-31 0.11
2018-09-30 0.11
2018-06-30 0.10
2018-03-31 0.09
2017-12-31 0.08
2017-09-30 0.04
2017-06-30 0.10
2017-03-31 0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Enlabs is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Enlabs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Enlabs has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Enlabs performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Enlabs's growth in the last year to its industry (Hospitality).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Enlabs has delivered over 20% year on year earnings growth in the past 5 years.
  • Enlabs's 1-year earnings growth is less than its 5-year average (37.5% vs 52.2%)
  • Enlabs's earnings growth has exceeded the DE Hospitality industry average in the past year (37.5% vs -36.8%).
Earnings and Revenue History
Enlabs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Enlabs Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8NL Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 39.61 9.44 15.14
2019-09-30 36.84 9.23 17.90
2019-06-30 34.40 8.51 16.92
2019-03-31 31.97 7.66 16.23
2018-12-31 30.10 6.86 15.56
2018-09-30 28.92 6.29 14.73
2018-06-30 27.75 5.89 14.09
2018-03-31 26.03 5.43 12.94
2017-12-31 23.01 4.48 11.58
2017-09-30 14.83 2.36 11.61
2017-06-30 16.36 5.47 10.43
2017-03-31 16.07 4.60 10.39
2016-12-31 17.26 3.74 10.80
2016-09-30 21.42 3.72 6.60
2016-06-30 16.50 -1.42 7.68
2016-03-31 14.17 -1.62 7.94
2015-12-31 11.23 -1.42 7.78
2015-09-30 9.90 -0.94 7.34
2015-06-30 8.68 -0.08 6.54
2015-03-31 7.72 0.23 5.62
2014-12-31 6.46 -0.14 5.08
2014-09-30 5.66 0.59 4.86
2014-06-30 5.11 4.43 4.41
2014-03-31 6.14 4.65 5.22
2013-12-31 7.56 5.58 5.54
2013-09-30 9.58 5.26 6.17
2013-06-30 11.00 1.20 6.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Enlabs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Enlabs used its assets more efficiently than the DE Hospitality industry average last year based on Return on Assets.
  • Enlabs has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Enlabs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Hospitality industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Enlabs has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Enlabs's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Enlabs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Enlabs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Enlabs's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Enlabs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.0019608450974E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Enlabs Company Filings, last reported 3 months ago.

DB:8NL Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 40.01 0.00 18.53
2019-09-30 37.47 0.00 15.66
2019-06-30 34.90 0.00 14.39
2019-03-31 32.43 0.00 12.06
2018-12-31 31.47 0.00 11.93
2018-09-30 29.24 0.00 8.48
2018-06-30 27.33 0.00 7.48
2018-03-31 26.05 0.00 6.74
2017-12-31 24.88 0.00 7.32
2017-09-30 19.62 0.00 2.50
2017-06-30 18.19 0.00 10.81
2017-03-31 17.49 0.00 10.08
2016-12-31 16.96 0.00 10.25
2016-09-30 16.89 0.00 10.93
2016-06-30 12.83 0.00 11.46
2016-03-31 13.49 0.00 6.24
2015-12-31 13.73 0.00 6.72
2015-09-30 8.12 0.00 4.81
2015-06-30 8.71 0.00 5.04
2015-03-31 9.02 0.00 6.12
2014-12-31 9.03 0.00 6.16
2014-09-30 9.32 0.00 6.02
2014-06-30 8.72 0.00 3.72
2014-03-31 8.81 0.00 3.92
2013-12-31 9.56 0.00 4.31
2013-09-30 8.79 0.00 5.37
2013-06-30 4.40 0.00 3.78
  • Enlabs's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Enlabs's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (5.2115654887932E+18%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 81.1x coverage).
X
Financial health checks
We assess Enlabs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Enlabs has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Enlabs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Enlabs dividends.
If you bought €2,000 of Enlabs shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Enlabs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Enlabs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8NL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Germany Hospitality Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 11.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8NL Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06
DB:8NL Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2014-11-24 0.000 0.000
2014-08-22 0.000 0.000
2014-05-06 0.000 0.000
2014-02-21 0.000 0.000
2013-04-25 0.011 3.510
2013-02-21 0.012 2.729

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Enlabs has not reported any payouts.
  • Unable to verify if Enlabs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Enlabs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Enlabs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Enlabs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Enlabs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Enlabs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Enlabs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
George Ustinov
TENURE AS CEO 0.2 years
CEO Bio

Mr. George Ustinov has been Chief Executive and President at Enlabs AB (publ) since February 2020. Mr. Ustinov was the Chief Operating Officer at Enlabs AB (publ) from December 2019 until February 2020 and served as Chief Financial Officer until December 2019. Mr. Ustinov joined the group in 2017 and has a bachelors degree in economics and management from University of Latvia. Previously he has undertaken leadership positions at global fast paced online consumer lender Creamfinance and financial audit team at Ernst & Young.

CEO Compensation
  • Insufficient data for George to compare compensation growth.
  • Insufficient data for George to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Enlabs management team in years:

0.3
Average Tenure
  • The average tenure for the Enlabs management team is less than 2 years, this suggests a new team.
Management Team

George Ustinov

TITLE
CEO & President
TENURE
0.2 yrs

Adam Jonsson

TITLE
Chief Financial Officer
TENURE
0.3 yrs

Davit Khatiashvili

TITLE
Chief Technology Officer
TENURE
1.3 yrs

Alnis Vitols

TITLE
Head of Legal
TENURE
1 yrs

Smooth Winbo

TITLE
Market Manager

Sami Koponen

TITLE
Head of Media

Dainis Niedra

TITLE
Managing Director of Central Eastern Europe
TENURE
0.3 yrs

Julius Järvinen

TITLE
Managing Director of Northwestern Europe
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Enlabs board of directors in years:

2.9
Average Tenure
51
Average Age
  • The average tenure for the Enlabs board of directors is less than 3 years, this suggests a new board.
Board of Directors

Niklas Braathen

TITLE
Chairman of the Board of Directors
COMPENSATION
€8K
AGE
56
TENURE
6.9 yrs

Peter Åström

TITLE
Director
COMPENSATION
€208K
AGE
53
TENURE
6.9 yrs

Staffan Dahl

TITLE
Independent Director
COMPENSATION
€9K
AGE
45
TENURE
2.9 yrs

Ludwig Pettersson

TITLE
Independent Director
COMPENSATION
€9K
AGE
28
TENURE
2.9 yrs

Christian Haupt

TITLE
Independent Director
COMPENSATION
€5K
AGE
51
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • Enlabs individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 20 Sell Ludwig Pettersson Individual 25. Mar 20 25. Mar 20 -150,000 €1.02 €-153,183
20. Feb 20 Buy Ludwig Pettersson Individual 20. Feb 20 20. Feb 20 26,851 €2.03 €54,392
09. Aug 19 Sell Staffan Dahl Individual 08. Aug 19 09. Aug 19 -20,500 €2.02 €-41,252
X
Management checks
We assess Enlabs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Enlabs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Enlabs AB (publ) creates entertainment in gaming, media, and solutions business areas. It offers entertainment through various products, including casino, live casino, betting, poker, and bingo under various brands. The company is also involved in the performance-based marketing activities; and delivering of sports results and technical solutions in the online gaming industry. It operates in Sweden, Malta, Baltics, and internationally. The company was formerly known as Nordic Leisure AB and changed its name to Enlabs AB (publ) in November 2018. Enlabs AB (publ) was founded in 2005 and is based in Sigtuna, Sweden.

Details
Name: Enlabs AB (publ)
8NL
Exchange: DB
Founded: 2005
SEK87,422,351
62,829,079
Website: http://enlabs.se
Address: Enlabs AB (publ)
Stora Gatan 46,
Sigtuna,
Stockholm County, 193 30,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM NLAB Share Capital OMX Nordic Exchange Stockholm SE SEK 14. Jul 2006
DB 8NL Share Capital Deutsche Boerse AG DE EUR 14. Jul 2006
Number of employees
Current staff
Staff numbers
198
Enlabs employees.
Industry
Casinos and Gaming
Consumer Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:38
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/02/06
Last earnings filing: 2020/01/30
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.